Nine Chapters Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Nine Chapters Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,130	Closed	-$9K	–	286
2016 Q4	$9K	Buy	+2,130	New	+$9.52K	0.02%	171
2015 Q3	–	Sell	-3,510	Closed	-$68K	–	1136
2015 Q2	$68K	Buy	3,510 +1,980	+129%	+$41.1K	0.01%	897
2015 Q1	$27K	Buy	+1,530	New	+$30K	﹤0.01%	937

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Nine Chapters Capital Management's PLX Position: Q1 2017 in Review

Nine Chapters Capital Management sold out of Protalix BioTherapeutics (PLX) in Q1 2017, closing a stake of 2,130 shares — an estimated $9K sold.

Nine Chapters Capital Management first reported a position in PLX in Q1 2015 and held it in 3 quarters. The position peaked at $68K in Q2 2015. 28 funds tracked by Wall St. Rank hold PLX as of Q1 2017.

Nine Chapters Capital Management reported no remaining Protalix BioTherapeutics position as of Q1 2017 after selling out during the quarter.
Nine Chapters Capital Management sold 2,130 Protalix BioTherapeutics shares in Q1 2017, an estimated $9K.
Nine Chapters Capital Management first reported a position in Protalix BioTherapeutics in Q1 2015 and held it in 3 quarters.
Nine Chapters Capital Management's Protalix BioTherapeutics position peaked at $68K in Q2 2015.
28 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2017.

Based on Nine Chapters Capital Management's 13F filing for Q1 2017, filed 8 May 2017.